GSK-3528869A

N/A

Report date: 2025/03/26 08:49:25

Base Information

Drug NameGSK-3528869A

Drug Alias NameChAd155-hIi-HBV + MVA-HBV + HBc-HBs/AS01B-4 adjuvanChAd155-hIi-HBV/MVA-HBV /HBc-HBs/AS01B-4 adjuvanChAd155-hIi-HBV + MVA-HBV prime-boost vaccine + HBc-HBs/AS01B-4 adjuvantRecombinant chimpanzee adenovirus type 155 HBV vaccine (GSK)GSK-3528869 +[6]

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccineBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHBsAg inhibitorsCapsid protein inhibitors

TargetsHepatitis B Surface AntigensCapsid protein

Therapy Area/IndicationsHepatitis B, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumBulgariaSingapore +[14]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsHepatitis B, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A